Teriflunomide (Aubagio) Effects on Cognitive and Vocational Outcomes, as Related to Neurodegeneration in Multiple Sclerosis: A Prospective, Observational, Single-blinded Study.
Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 27 Apr 2017
At a glance
- Drugs Teriflunomide (Primary)
- Indications Multiple sclerosis
- Focus Therapeutic Use
- 24 Apr 2017 Planned End Date changed from 1 Feb 2017 to 5 Aug 2019.
- 24 Apr 2017 Planned primary completion date changed from 1 Feb 2017 to 1 Aug 2018.
- 21 Apr 2016 Status changed from recruiting to active, no longer recruiting, according to the results published.